Atria Investments’s Intellia Therapeutics NTLA Stock Holding History

Atria Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222K	Buy	13,098 +22	+0.2%	+$308	﹤0.01%	2011
2026 Q1	$168K	Buy	13,076 +2,684	+26%	+$34.2K	﹤0.01%	1996
2025 Q4	$93.4K	Sell	10,392 -1	-0%	-$14	﹤0.01%	2007
2025 Q3	$179K	Buy	10,393 +176	+2%	+$2.17K	﹤0.01%	1964
2025 Q2	$95.8K	Buy	+10,217	New	+$83.9K	﹤0.01%	1967
2024 Q4	–	Sell	-23,099	Closed	-$475K	–	1943
2024 Q3	$475K	Buy	23,099 +4,511	+24%	+$104K	0.01%	1352
2024 Q2	$416K	Buy	+18,588	New	+$443K	0.01%	1399

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Atria Investments's NTLA Position: Q2 2026 in Review

Atria Investments increased its Intellia Therapeutics (NTLA) stake by 0.17% in Q2 2026, buying an estimated $308 and bringing the position to 13,098 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

Atria Investments first reported a position in NTLA in Q2 2024 and has held it in 7 quarters since. The position peaked at $475K in Q3 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Atria Investments held 13,098 shares of Intellia Therapeutics worth $222K as of Q2 2026.
Atria Investments bought 22 Intellia Therapeutics shares in Q2 2026, an estimated $308.
Intellia Therapeutics made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #2011 holding.
Atria Investments first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 7 quarters since.
Atria Investments's Intellia Therapeutics position peaked at $475K in Q3 2024.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.